Tetomilast: new promise for phosphodiesterase-4 inhibitors?
Stephen J Bickston, Kenneth R Snider, Matthew R Kappus
Virginia Commonwealth University Medical Center, VCUHS Center for Inflammatory Bowel Disease, MCV Campus, Box 980341, Richmond, VA 23298-0341, USA. sbickston@mcvh-vcu.edu
Expert opinion on investigational drugs 2012 DecTetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). Here, the authors review the pharmacology of the drug, and offer critical review of the available data for use of tetomilast in the treatment of IBD. Peer-reviewed publications, including Phase I and II clinical trials, all other formats included. Tetomilast may be beneficial in IBD. Small differences in molecules and in recombinant proteins can translate into substantial differences in clinical effects and toxicity in IBD. This is a reasonable approach when exploring new options like tetomilast.
Citation
Stephen J Bickston, Kenneth R Snider, Matthew R Kappus. Tetomilast: new promise for phosphodiesterase-4 inhibitors? Expert opinion on investigational drugs. 2012 Dec;21(12):1845-9
Mesh Tags
Substances
PMID: 23043390
View Full Text
